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Adhesion to medical device and host cell surfaces are crucial steps during pathogenesis by fungi such as 
Candida albicans, which is especially dangerous to immunocompromised individuals such as AIDS 
patients.  We have identified a small molecule that inhibits adhesion of C. albicans to polystyrene and to 
cultured human epithelial cells.  Moreover, this compound is able to coat plastic surfaces and make 
them resistant to colonization by fungal biofilms.  Therefore, this compound has the potential to be 
widely useful as a novel therapeutic and/or as a coating on medical devices.  
 
Rationale:  C. albicans is the most widespread fungal pathogen of humans and one of the most frequent 
hospital-acquired infections.  The estimated annual cost of treating nosocomial Candida infections 
exceeds $1 billion per year.  As an opportunistic pathogen, it is responsible for common clinical 
problems including oral thrush and vaginitis, but can also lead to life-threatening systemic infections 
(candidiasis) in immunocompromised individuals, resulting in 30-50% mortality rates.  Contributing to 
these problems is the ability of C. albicans to develop resistance to antifungal drugs.  Moreover, most 
effective antifungal drugs also cause serious side effects, in many cases because of the significant 
homology between mammalian and fungal drug targets.  Therefore, new antifungal drugs are a high 
medical priority.  Surface adhesion, morphological switching, and biofilm formation are interrelated 
factors that contribute directly to C. albicans virulence.  Therefore, compounds that impair these 
processes would have promising properties as first step towards new antifungal therapeutics. 
 
Preliminary Studies:  Efficient adhesion is required for formation of aggressive biofilms, which in turn 
make Candida a successful pathogen.  Therefore, we identified compounds that prevent adhesion of 
Candida albicans to polystyrene surfaces.  Because the assays in this proposal are based on altering the 
behavior of intact cells, we avoid the complication of compounds unable to cross the cell wall and 
membranes. 
 
Our initial search for adhesion inhibitors was conceptually simple, based on dye binding to monitor 
yeast adhesion to surfaces.  We identified 41 compounds that reduced adhesion to <25% of the vehicle-
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only wells.  Retesting these compounds in a secondary assay measuring adhesion of a GFP-expressing 
Candida strain confirmed that most of the reordered compounds indeed inhibit adhesion to polystyrene 
(Figure 1). 
 
 
Human cell adhesion:  To determine whether any candidate compounds would affect interactions with 
biological targets as well as inert surfaces, we also tested how the candidate compounds affect C. 
albicans adherence to human cells, using monolayers of human lung epithelial cells.  The GFP-encoding 
cells allowed us to use both microscopy and fluorescence measurements to detect fungal cells that 
remained bound after washing.  We observed that “compound #4”, but not other candidate 
compounds, reduced the interaction of C. albicans with the human cells to background levels.  We also 
verified that compound 4 did not affect the viability of this human cell line, even at concentrations much 
higher (250 µM) than those used in the adhesion assay (data not shown). 
 
Plastic coating:  Compound 4 also inhibits Candida adhesion to polystyrene when it is incubated with the 
plastic prior to the addition of the cells.  Therefore, compound 4 not only has effects on Candida cell 
morphology in the absence of surface adhesion, it also renders plastic surfaces resistant to subsequent 
Candida binding.  Together, our data suggest that compound 4 may not only be effective at combating 
fungal infections, but could also have potential use as a compound to prevent multiple types of 
unwanted microbial colonization. 
Figure 1. Compound #4 inhibits C. albicans adhesion to polystyrene. 
GFP-expressing wild type or non-adherent edt1 mutant C. albicans 
cells were plated into 96 well plates with DMSO or 25 µM compound 4 
as indicated.  Plates were incubated for 4 hours at 37oC. Media was 
then decanted and plates were washed 3 times prior to fluorescence 
microscopy. 
